Olaitan Comfort Shekoni

Ms. Olaitan Comfort Shekoni

Animal Sciences, The Ohio State University, Columbus, Georgia, USA
orcid
Graduate Research Associate

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
DBDina Bugybayeva
Dina Bugybayeva
EDEkachai Dumkliang
Ekachai Dumkliang
Veerupaxagouda PatilVeerupaxagouda Patil
Veerupaxagouda Patil
GYGanesh Yadagiri
Ganesh Yadagiri
RSRaksha Suresh
Raksha Suresh
Renukaradhya GourapuraRenukaradhya Gourapura
Renukaradhya Gourapura
This study focuses on the development and characterization of an intranasal vaccine platform using adjuvanted nanoparticulate delivery of swine influenza A virus (SwIAV). The vaccine employed whole inactivated H1N2 SwIAV as an antigen and STING-agonist ADU-S100 as an adjuvant, with both surface adsorbed or encapsulated in mannose–chitosan nanoparticles (mChit-NPs). Optimization of mChit-NPs included evaluating size, zeta potential, and cytotoxicity, with a 1:9 mass ratio of antigen to NP demonstrating high loading efficacy and non-cytotoxic properties suitable for intranasal vaccination. In a heterologous H1N1 pig challenge trial, the mChit-NP intranasal vaccine induced cross-reactive sIgA antibodies in the respiratory tract, surpassing those of a commercial SwIAV vaccine. The encapsulated mChit-NP vaccine induced high virus-specific neutralizing antibody and robust cellular immune responses, while the adsorbed vaccine elicited specific high IgG and hemagglutinin inhibition antibodies. Importantly, both the mChit-NP vaccines reduced challenge heterologous viral replication in the nasal cavity higher than commercial swine influenza vaccine. In summary, a novel intranasal mChit-NP vaccine platform activated both the arms of the immune system and is a significant advancement in swine influenza vaccine design, demonstrating its potential effectiveness for pig immunization.

17 February 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
CLCarolyn Lee
Carolyn Lee
RSRaksha Suresh
Raksha Suresh
Patricia A. BoleyPatricia A. Boley
Patricia A. Boley
OSOlaitan Comfort Shekoni
Olaitan Comfort Shekoni
JSJennifer Schrock
Jennifer Schrock
Scott KenneyScott Kenney
Scott Kenney
Background/Objectives: African swine fever virus (ASFV), the causative agent of African swine fever (ASF), is a highly contagious virus affecting both domestic and feral pig populations with mortality rates approaching 100% within one week of infection. Currently, there are limited treatments or vaccines available to control the disease. Although ASF is endemic in sub-Saharan Africa, the virus has also spread widely, reaching regions of the European Union, Russia, China, Southeast Asia, and, more recently, to the Dominican Republic and Haiti, bringing the threat closer to the United States (U.S.). ASF introduction to the U.S. would have severe consequences for swine producers and the national pork industry. Consequently, there is an urgent need to develop effective vaccine strategies to manage ongoing outbreaks abroad and mitigate the risk of future ASF incursions. Recent efforts have identified several ASFV epitopes and evaluated them in experimental vaccine trials. However, these vaccine candidates have elicited limited protective immune responses and have not demonstrated full protective efficacy. Methods: In this study, we employed in silico modeling and epitope prediction tools to design a synthetic multiepitope ASF protein incorporating key immunogenic regions of ASFV. The goal was to generate a single-antigen construct capable of inducing broad and robust immune responses when formulated with an established nanoparticle-based vaccine platform. The multiepitope ASF protein was subsequently expressed and entrapped into mannose-conjugated chitosan (M-CS) nanoparticles for vaccine formulation. The candidate vaccine, formulated with M-CS nanoparticle-entrapped adjuvant (ADU S100), was administered intramuscularly to pigs, and both T- and B-cell responses were assessed following the primary (DPV 22) and booster (DPV 42) doses. Results: Our M-CS ASF protein vaccine elicited antigen-specific T- and B-cell responses, both of which are recognized as central correlates of protection against ASFV. Conclusions: These promising preliminary immunological findings suggest that this nanoparticle vaccine has the potential to confer protection against ASFV challenge, a hypothesis that will be examined in future studies.

17 October 2024 in Journal of Applied Poultry Research
Verified
Journal Article
Open access
JSJennifer Schrock
Jennifer Schrock
RSRaksha Suresh
Raksha Suresh
OSOlaitan Comfort Shekoni
Olaitan Comfort Shekoni
DBDina Bugybayeva
Dina Bugybayeva
SDSara Dolatyabi
Sara Dolatyabi
GRGourapura J Renukaradhya
Gourapura J Renukaradhya

22 September 2026 in Poultry Science
Verified
Journal Article
Open access
OSOlaitan Comfort Shekoni
Olaitan Comfort Shekoni
Ekramy SayedahmedEkramy Sayedahmed
Ekramy Sayedahmed
WWWen-Chien Wang
Wen-Chien Wang
RSRaksha Suresh
Raksha Suresh
JSJennifer Schrock
Jennifer Schrock
Renukaradhya GourapuraRenukaradhya Gourapura
Renukaradhya Gourapura